SPRY ARS Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1671858 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-14.5%
TTM net income YoY-149.7%
TTM EPS YoY-148.1%
Revenue 3-yr CAGR1,496.8%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-161.5%
Net margin-163.6%
FCF margin-149.9%
EBITDA margin-160.2%
Returns
ROE-294.6%
ROA-64.0%
ROIC (approx.)-116.0%
Asset turnover0.39x
Leverage & solvency
Liabilities / assets104.8%
Debt / equity—
Current ratio3.25x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.92x
Accruals ratio-5.4%
Payout ratio—
Capex / revenue0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $84.28M | $89.15M | $30,000 | $1.32M | $5.51M |
| Cost of revenue | — | — | $0 | — | — |
| Gross profit | — | — | $30,000 | — | — |
| R&D expense | $13.18M | $19.58M | $20.27M | $18.38M | $20.27M |
| SG&A expense | $230.12M | $71.67M | $47.28M | $603,000 | $4.69M |
| Operating income | -$179.45M | -$3.08M | -$67.52M | -$35.52M | -$19.45M |
| Pretax income | -$171.38M | $8.29M | -$54.37M | — | — |
| Income tax | -$80,000 | $288,000 | $0 | $0 | $0 |
| Net income | -$171.30M | $8.00M | -$54.37M | -$34.68M | -$20.24M |
| EBITDA | -$178.08M | -$3.00M | -$67.42M | -$35.42M | -$19.24M |
| EPS (basic) | -1.74 | 0.08 | -0.57 | -0.87 | -0.70 |
| EPS (diluted) | -1.74 | 0.08 | -0.57 | -0.87 | -0.70 |
| Weighted avg. shares (diluted) | 98.57M | 102.39M | 95.22M | 39.96M | 28.87M |
| Banking | |||||
| Net interest income | — | — | — | — | $106,000 |
| Balance sheet | |||||
| Cash & equivalents | $41.32M | $50.82M | $70.97M | $210.52M | $60.06M |
| Short-term investments | $203.67M | $263.20M | $157.39M | $63.86M | $0 |
| Receivables | $25.35M | $8.18M | $0 | — | — |
| Inventory | $31.42M | $10.52M | $0 | — | — |
| Current assets | $284.90M | $334.30M | $231.73M | $277.70M | $60.73M |
| PP&E, net | $2.46M | $1.07M | $574,000 | $329,000 | $72,000 |
| Intangibles | $14.45M | $7.37M | $0 | — | — |
| Total assets | $327.65M | $351.15M | $233.19M | $281.44M | $61.45M |
| Current liabilities | $39.15M | $23.44M | $2.39M | $5.44M | $8.19M |
| Long-term debt | $96.37M | $0 | — | — | — |
| Total debt | $96.37M | $0 | — | — | — |
| Total liabilities | $213.39M | $94.36M | $2.43M | $8.55M | $16.68M |
| Shareholders' equity | $114.26M | $256.80M | $230.76M | $272.89M | -$31.27M |
| Net debt | $55.06M | -$50.82M | — | — | — |
| Shares outstanding | 99.29M | 97.95M | 96.41M | 93.94M | 30.37M |
| Cash flow statement | |||||
| Operating cash flow | -$170.87M | $13.55M | -$59.27M | -$40.08M | -$17.56M |
| Capital expenditure | $339,000 | $563,000 | $175,000 | $199,000 | $55,000 |
| Free cash flow | -$171.21M | $12.98M | -$59.44M | -$40.28M | -$17.62M |
| Investing cash flow | $56.77M | -$106.10M | -$87.18M | -$199,000 | -$55,000 |
| Financing cash flow | $104.60M | $72.40M | $6.90M | $190.73M | $53.16M |
| Depreciation & amortization | $1.37M | $79,000 | $100,000 | $100,000 | $213,000 |
| Stock-based compensation | $22.09M | $14.53M | $9.23M | $5.84M | $2.83M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.